Clinical trial
The Assessment of Cysteinyl Leukotriene Receptor Antagonist Role in Inhibition of Atherosclerosis, Proliferation and Its Influence on Endothelial Function in Patients Undergoing Endovascular Treatment Due to Peripheral Arterial Disease.
NCT04277702 is registered in ClinicalTrials.gov with Jagiellonian University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Assessment of Cysteinyl Leukotriene Receptor Antagonist Role in Inhibition of Atherosclerosis, Proliferation and Its Influence on Endothelial Function in Patients Undergoing Endovascular Treatment Due to Peripheral Arterial Disease.
- Lead sponsor
- Jagiellonian University
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- May 31, 2020
- Completion date
- December 31, 2023
- Enrollment
- 200 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
atherosclerosis of artery, lower limb ischemia, peripheral arterial disease, peripheral vascular diseases